

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Singh Vanila</u>  (Last) (First) (Middle) 4131 PARKLAKE AVE. SUITE 225  (Street) RALEIGH NC 27612  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIODELIVERY SCIENCES INTERNATIONAL INC [ BDSI ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/23/2021	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/23/2021		M		4,000	A	\$0 <sup>(1)</sup>	22,834	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Options (right to buy)	\$3.76	08/23/2021		A		48,000		(2)	08/23/2031	Common Stock	48,000	\$3.76	48,000	D	
Restricted Stock Units	\$0.0	08/23/2021		A		8,000		(1)	08/23/2022	Common Stock	8,000	\$0	8,000	D	
Restricted Stock Units	\$0.0	08/23/2021		M		4,000		(1)	08/23/2022	Common Stock	4,000	\$0	4,000	D	

Explanation of Responses:

- The restricted stock units ("RSUs") were issued to the Reporting Person on August 23, 2021 (the "Effective Date"), as compensation for service on the Company's board of directors. The RSUs vest as follows: (i) 4,000 RSUs vested in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and (ii) 4,000 RSUs will vest upon the earlier of (i) the first anniversary of the Effective Date or (ii) the Company's 2022 Annual Meeting of Stockholders.
- The stock options ("options") were issued to the Reporting Person on the Effective Date, as compensation for service on the Issuer's board of directors. The options vest as follows: (i) 24,000 options vested in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and (ii) 24,000 options will vest upon the earlier of (i) the first anniversary of the Effective Date or (ii) the Company's 2022 Annual Meeting of Stockholders.

Remarks:

Dr. Vanila M. Singh

08/25/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.